Control of Acute Zollinger-Ellison Syndrome With Intravenous Omeprazole

Blanchi, A.; Delchier, Jean‐Charles; Soulé, Jean–Claude; Payen, D; Bader, J P

doi:10.1016/s0140-6736(82)91246-6

Cited by 32 publications

(12 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[1][2][3] . Used in the treatment of peptic ulcers, [4,5] reflux oesophagitis, [6] and the Zollinger-Ellison syndrome, [7,8] omeprazole is a lipophilic, weak base with pKa1 = 4.2 and PKa2 = 9 and is subject to degradation processes, unless protected against acidic conditions. [2] The number of its decomposition products have been elucidated and characterized by Brändström et al under different conditions.…”

Section: Introductionmentioning

confidence: 99%

Spectrophotometric and chromatographic determination of omeprazole in pharmaceutical formulations

Gallardo

López-Viota

Sierra

et al. 2009

Pharmaceutical Development and Technology

View full text Add to dashboard Cite

The purpose of this study was to determine the stability of the pH sensitive drug, omeprazole, within different solid oral pharmaceutical formulations and to determine whether the addition of antacid and surfactant agents, at varying concentrations, influenced drug stability and release. Spectrophotometric and chromatographic techniques were used for evaluation purposes, giving good results concerning linearity, precision and specificity within the range of concentrations used in this study. However, the results show that the degradation products of omeprazole interfere with spectrophotometric evaluation, making this technique insufficiently selective for omeprazole. On the other hand, liquid chromotography proved to be more sensitive, accurate and precise. Additionally, in an attempt to improve the administration form of the drug, an extemporaneous suspension was designed, which after evaluation proved to be a satisfactory administration vehicle. The best formulation of omeprazole studied is: omeprazole: 0.5%; corn starch 34.2%; aluminum hydroxide 26%; magnesium hydroxide 13%; simple syrup 24.8%; SDS 1%.

show abstract

Section: Introductionmentioning

confidence: 99%

Spectrophotometric and chromatographic determination of omeprazole in pharmaceutical formulations

Gallardo

López-Viota

Sierra

et al. 2009

Pharmaceutical Development and Technology

View full text Add to dashboard Cite

show abstract

“…A dramatic and sustained reduction of gastric acid secretion was also reported by Mignon et al [8] in a severe case of Zollinger-Ellison syndrome during repeated measurements of basal acid output (BAO) and 24-hour intragastric pH recording. A group of French investigators [9,10] reported the effect of a single i.v. dose of 60 mg omeprazole in a patient with Zollinger-Ellison syndrome.…”

Section: Omeprazole In Zollinger-ellison Syndromementioning

confidence: 99%

“…There are also some case reports of long term treatment reporting adequate and sta ble control of acid secretion by doses of 60-90 mg omeprazole daily [9,12]. Until now there is only 1 case report that suggests resis tance to omeprazole in Zollinger-Ellison syn drome [20].…”

Section: Omeprazole In Zollinger-ellison Syndromementioning

confidence: 99%

“…The first publication on the efficacy of omeprazole in the treatment of acid-related symptoms in a Zollinger-Ellison syndrome patient was reported in 1982 [9], The study concerned a young patient with multiple en docrine neoplasia type I (pituitary dysfunc tion, hyperparathyroidism, and Zollinger-El lison syndrome) with severe diarrhea, multi ple duodenal ulcers and a jejunal resection for a perforated jejunal ulcer. Acid hyperse cretion could not be controlled by intrave nous administration of 2.4 g cimetidine dai ly.…”

Section: Efficacy O F Omeprazole On Symptom Reliefmentioning

confidence: 99%

See 1 more Smart Citation

Omeprazole in the Treatment of Zollinger-Ellison Syndrome and Histamine H<sub>2</sub>-Antagonist Refractory Ulcers

Meijer

Jansen²,

Lamers³

1989

Digestion

View full text Add to dashboard Cite

Omeprazole is a very potent and long-acting inhibitor of gastric acid secretion. These characteristics make the drug very suitable for the management of gastric acid hyper-secretion and symptom relief in patients with the Zollinger-Ellison syndrome, and in the treatment of patients with ulcers resistant to histamine H₂-receptor antagonists. Most patients require only a once-daily dose, whereas in about 30% of patients with Zollinger-Ellison syndrome the dose has to be split. During long-term treatment the required dose of omeprazole is usually rather stable. Up until now neither in patients with Zollinger-Ellison syndrome nor in those with resistant ulcers have convincing reports of resistance to omeprazole been published. However, a relative disadvantage of omeprazole is the observation that symptom-free Zollinger-Ellison syndrome patients are less inclined to undergo the work-up for surgery, which is the only possible curative treatment for these patients. Omeprazole therapy has been well tolerated and no side effects, significant changes in laboratory variables or toxicity have been noted.

show abstract

“…It is among proton pump inhibitors (PPI) and shows powerful inhibitory action against secretion of gastric juice and is used in treatment of duodenal and gastric ulcers, erosive or ulcerative gastroesophageal reflux disease (GERD), and pathological hypersecretory conditions (Zollinger-Ellison) [ 2 ]. However, omeprazole is susceptible to degradation/transformation in acid reacting and neural media [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Preformulation Studies for Generic Omeprazole Magnesium Enteric Coated Tablets

Migoha

Ratansi

Kaale

et al. 2015

BioMed Research International

View full text Add to dashboard Cite

Preformulation is an important step in the rational formulation of an active pharmaceutical ingredient (API). Micromeritics properties: bulk density (BD) and tapped density (TD), compressibility index (Carr's index), Hauser's ratio (H), and sieve analysis were performed in order to determine the best excipients to be used in the formulation development of omeprazole magnesium enteric coated tablets. Results show that omeprazole magnesium has fair flow and compressibility properties (BD 0.4 g/mL, TD 0.485 g/mL, Carr's index 17.5%, Hauser's ratio 1.2, and sieve analysis time 5 minutes). There were no significant drug excipient interactions except change in colour in all three conditions in the mixture of omeprazole and aerosil 200. Moisture content loss on drying in all three conditions was not constant and the changes were attributed to surrounding environment during the test time. Changes in the absorption spectra were noted in the mixture of omeprazole and water aerosil only in the visible region of 350–2500 nm. Omeprazole magnesium alone and with all excipients showed no significant changes in omeprazole concentration for a 30-day period. Omeprazole magnesium formulation complies with USP standards with regards to the fineness, flowability, and compressibility of which other excipients can be used in the formulation.

show abstract

Control of Acute Zollinger-Ellison Syndrome With Intravenous Omeprazole

Cited by 32 publications

References 3 publications

Spectrophotometric and chromatographic determination of omeprazole in pharmaceutical formulations

Spectrophotometric and chromatographic determination of omeprazole in pharmaceutical formulations

Omeprazole in the Treatment of Zollinger-Ellison Syndrome and Histamine H<sub>2</sub>-Antagonist Refractory Ulcers

Preformulation Studies for Generic Omeprazole Magnesium Enteric Coated Tablets

Contact Info

Product

Resources

About